Salarius Pharmaceuticals Management
Management criteria checks 1/4
Salarius Pharmaceuticals' CEO is Rick Pierce, appointed in Nov 2025, has a tenure of less than a year. directly owns 0.26% of the company’s shares, worth $10.83K. The average tenure of the management team and the board of directors is 0.2 years and 6.5 years respectively.
Key information
Rick Pierce
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.3% |
| Management average tenure | less than a year |
| Board average tenure | 6.5yrs |
Recent management updates
No updates
Recent updates
CEO
Rick Pierce (63 yo)
Mr. Frederick E. Pierce, II, also known as Rick, is CEO & Director of Salarius Pharmaceuticals, Inc. from November 12, 2025. Mr. Pierce Mr. Pierce serves as Chief Executive Officer at Decoy Therapeutics In...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP & CFO | 6.3yrs | US$350.42k | 0.32% $ 13.1k | |
| CEO & Director | less than a year | no data | 0.26% $ 10.8k | |
| Chief Scientific Officer & Director | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | 5.5yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data |
Experienced Management: SLRX's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | 0.26% $ 10.8k | |
| Chief Scientific Officer & Director | less than a year | no data | no data | |
| Independent Director | 5.6yrs | US$52.44k | 0.00039% $ 16.2 | |
| Lead Independent Director | 6.5yrs | US$61.69k | 0.00022% $ 9.1 | |
| Independent Director | 6.5yrs | US$62.44k | 0.078% $ 3.3k | |
| Independent Chairman of the Board | 6.5yrs | US$74.94k | 0.00038% $ 15.8 | |
| Independent Director | 6.5yrs | US$57.94k | 0.00036% $ 14.9 |
Experienced Board: SLRX's board of directors are considered experienced (6.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/07 05:58 |
| End of Day Share Price | 2026/01/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Salarius Pharmaceuticals, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aydin Huseynov | Benchmark Company |
| Michael King | H.C. Wainwright & Co. |